This year’s Tour de France had no positive drug test results, Cycling Anti-Doping Foundation (CADF) director Francesca Rossi said at a media open day in Aigle, Switzerland, on Tuesday.
Britain’s Chris Froome won this year’s race, which came under extra scrutiny as it was the first edition being staged since Lance Armstrong admitted he had cheated his way to seven Tour de France titles from 1999 to 2005.
Sky ProCycling’s Froome, who had to face the media every day on the Tour, expressed his frustration at being repeatedly questioned about doping in the sport.
Sky principal Dave Brailsford said during the three-week Tour that he was ready to give the World Anti-Doping Agency (WADA) all their team training data if that would help.
An International Cycling Union (UCI) statement on Tuesday said the CADF took 622 blood and urine samples during the 100th edition of the Tour against 566 samples last year.
Working closely with the French Anti-Doping Agency (AFLD), the CADF took 202 pre-competition samples and 419 during the race.
Reinforcing the strategy of targeted testing, 198 of the samples taken during this year’s race were for the biological passport compared with 149 samples last year.
“This target testing strategy has been hugely facilitated by the excellent on-site cooperation between CADF and AFLD during the race,” Rossi was quoted as saying on the UCI’s official Web site.
The samples were analyzed by WADA-accredited laboratories in France, Switzerland and Germany.
The UCI and AFLD have also agreed to keep the samples taken for possible retrospective testing in the future.